Bristol Myers Squibb announced a significant partnership with China's Hengrui Pharma to jointly develop new drugs, marking a notable shift in cross-continent pharmaceutical collaboration [1]. The deal, described as potentially worth billions of dollars, will see the two companies work together on about a dozen drugs, including four experimental medicines discovered by Bristol that will be sent to China for early-stage clinical trials conducted by Hengrui [1]. In addition to developing these drugs, the companies will collaborate on discovering new treatments, signaling a more reciprocal and integrated approach to global drug development [1].
Industry experts highlight the uniqueness of this agreement. Michael Baran, head of private investments at Affinity Asset Advisors, noted that while U.S. drugmakers have previously partnered with Chinese firms, Bristol's deal stands out for its reciprocal nature and the potential to accelerate drug development by leveraging China's capabilities [1]. This partnership could pave the way for more U.S. pharmaceutical companies to conduct early-stage drug development in China and for Chinese firms to become more prominent on the global stage [1].
Data from DealForma indicates a growing trend of American and European biopharmaceutical companies turning to China for new drug candidates, with over half of large pharmaceutical licensing deals this year originating from China, compared to 39% last year and just 5% in 2022 [1]. Traditionally, large drugmakers have licensed drugs discovered and tested in China, but Bristol's approach of sending its own experimental drugs to China for development marks a departure from this model [1].
Lieven Van der Veken, a senior partner at McKinsey, emphasized that this partnership is distinct from previous collaborations, such as Hengrui's recent deal with GSK, as it involves Bristol acknowledging and utilizing China's growing role in global pharmaceutical research and development [1].
CONCLUSION
Bristol Myers Squibb's partnership with Hengrui Pharma represents a strategic evolution in cross-border drug development, with both companies contributing assets and expertise. This deal underscores China's rising importance in the pharmaceutical industry and could influence how global drugmakers approach early-stage research and development. Market participants are likely to view this as a high-impact move that may accelerate innovation and reshape industry collaboration models.